Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000 and 1 million yuan, and 15% earning between 1 million and 2 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Pharmaceutical, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries ranging from 1.3935 million to 2.5587 million yuan [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, while 3% received between 300 and 1,000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Pharmaceutical, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions ranging from 207 to 410 times [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (27 individuals, 39%), between 500,000-1,000,000 yuan (29 individuals, 42%), between 1,000,000-2,000,000 yuan (10 individuals, 15%), between 2,000,000-3,000,000 yuan (2 individuals, 3%), and above 3,000,000 yuan (1 individual, 1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earners and Investor Relations - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu (2.5587 million yuan) - Cao Wei from Jichuan Pharmaceutical (2.4107 million yuan) - Yu Jie from Tian Shi Li (2.525 million yuan) - Wu Rui from Yiling Pharmaceutical (1.89 million yuan) - Jiang Xianhong from Yibai Pharmaceutical (1.3935 million yuan) [7] - The frequency of investor meetings varies significantly among companies, with 41 companies hosting fewer than 10 meetings annually (59%), 17 companies holding 10-100 meetings (25%), 9 companies conducting 100-300 meetings (13%), and 2 companies having 300-1000 meetings (3%) [7] Most Active Companies in Investor Relations - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical (410 meetings) - Qizheng Tibetan Medicine (404 meetings) - Yunnan Baiyao (298 meetings) - Jinghua Pharmaceutical (221 meetings) - Pian Zai Huang (207 meetings) [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: - Below 500,000 yuan: 27 individuals (39%) - 500,000-1,000,000 yuan: 29 individuals (42%) - 1,000,000-2,000,000 yuan: 10 individuals (15%) - 2,000,000-3,000,000 yuan: 2 individuals (3%) - Above 3,000,000 yuan: 1 individual (1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - The educational background indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu: 2.5587 million yuan - Cao Wei from Jichuan Pharmaceutical: 2.4107 million yuan - Yu Jie from Tianjin Tasly: 2.525 million yuan - Wu Rui from Yiling Pharmaceutical: 1.89 million yuan - Jiang Xianhong from Yibai Pharmaceutical: 1.3935 million yuan - Their tenure at the companies ranges from less than 1 year to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies: - Less than 10 meetings: 41 companies (59%) - 10-100 meetings: 17 companies (25%) - 100-300 meetings: 9 companies (13%) - 300-1000 meetings: 2 companies (3%) [7] - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical: 410 meetings - Qizheng Pharmaceutical: 404 meetings - Yunnan Baiyao: 298 meetings - Jinghua Pharmaceutical: 221 meetings - Pianzihuang: 207 meetings [9]

Group 1 - The Yarlung Tsangpo River downstream hydropower project has officially commenced with a total investment of approximately 1.2 trillion yuan, aiming to build five tiered power stations primarily for electricity transmission and local consumption in Tibet [1] - The Ministry of Industry and Information Technology (MIIT) plans to accelerate the development of biomanufacturing and low-altitude industries, while promoting innovation in future industries such as humanoid robots and brain-computer interfaces [2][3] - The MIIT and the National Development and Reform Commission (NDRC) are set to issue work plans to stabilize growth in key industries including steel, non-ferrous metals, petrochemicals, and building materials [2][3] Group 2 - The U.S. Department of Commerce has imposed a preliminary anti-dumping duty of 93.5% on Chinese imported anode-grade graphite, citing unfair subsidies [5] - The State Administration for Market Regulation has urged major platform companies like Ele.me, Meituan, and JD.com to standardize promotional activities and foster a healthy competitive environment in the food service industry [6] - A meeting was held to discuss the regulation of the new energy vehicle industry, focusing on enhancing supervision and monitoring product prices and quality [8] Group 3 - The China Iron and Steel Association has proposed a new mechanism for capacity governance to prevent overcapacity risks in the steel industry and to eliminate irrational competition [10] - Yu Shu Technology has initiated its listing guidance, with its controlling shareholder holding approximately 34.76% of the company's shares [11] - Multiple provinces are planning to establish companies to develop local cultural creative Moutai liquor, with participation from distributors based on their allocation of Moutai products [12] Group 4 - As of July 18, 1551 A-share listed companies have released performance forecasts for the first half of 2025, with 26 companies expecting a net profit increase of over 1000% year-on-year [14] - Longhua Automobile reported a net profit of 6.337 billion yuan for the first half of the year, reflecting a year-on-year decline of 10.22% [19] - The major shareholder of Hongbaoli plans to reduce its stake by up to 2% [20]

Core Viewpoint - The company has announced a cash dividend distribution plan for the fiscal year 2024, with a total cash dividend amounting to 24,946,612.40 RMB, distributing 0.50 RMB per 10 shares to all shareholders [1][2][3]. Summary by Sections Dividend Distribution Plan - The company will distribute a cash dividend of 0.50 RMB per 10 shares (including tax) to all shareholders, with no stock dividends or capital reserve transfers [2][3]. - The total cash dividend amount is calculated based on the total share capital of 498,932,248 shares, resulting in a total distribution of 24,946,612.40 RMB [1][5]. Ex-Dividend Price Adjustment - The ex-dividend price will be adjusted by subtracting 0.0486609 RMB per share from the closing price on the trading day before the ex-dividend date [2][6]. - The adjusted ex-dividend price will affect the ongoing stock options, changing the exercise price from 6.24 RMB to 6.19 RMB per share [6]. Dividend Payment Dates - The record date for the dividend distribution is set for July 24, 2025, and the ex-dividend date is July 25, 2025 [3][4]. Eligible Shareholders - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [4]. Taxation on Dividends - Different tax rates will apply based on the type of shares held, with specific provisions for Hong Kong investors and domestic investors regarding the withholding of individual income tax [3].

证券代码：002728 证券简称：特一药业 公告编号：2025-051 特一药业集团股份有限公司 2024 年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、公司 2024 年度利润分配方案为：以公司现有总股本 512,661,866 股剔除已回购 股份 13,729,618 股后的股本 498,932,248 股为基数，按分配比例不变的原则，向全体 股东每 10 股派发现金红利 0.500000 元（含税），不送红股，不以公积金转增股本。 2、鉴于公司回购专户上的股份不参与 2024 年度权益分派，公司本次实际现金分红 的总金额为 24,946,612.40 元（实际现金分红的总金额=实际参与分配的总股本×每股 分配比例，即 24,946,612.40 元=498,932,248 股×0.0500000 元/股）。因公司已购回 的股份不参与分红，实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一 股的比例将减小。因此，本次权益分派实施后除权除息价格计算时，按公司总股本（含 回购专户股份）折算的每股现金红利应以 0. ...

Core Points - The Nomination Committee of the Board of Directors of Te Yi Pharmaceutical Group Co., Ltd. has reviewed the qualifications of the proposed senior management personnel and found them to meet the necessary criteria for their roles [1][2] - The proposed senior management candidates have not faced any penalties from the China Securities Regulatory Commission or other relevant authorities, nor have they been subject to any criminal investigations or violations [1] - Ms. Xu Zilan has been nominated as the Secretary of the Board and possesses the necessary qualifications and professional capabilities for the role, including a recognized Secretary qualification certificate from the Shenzhen Stock Exchange [1][2] Summary by Sections - **Nomination Process**: The nomination process for the senior management personnel has complied with the Company Law and relevant regulations, with the candidates' consent obtained [1] - **Qualifications of Candidates**: The proposed candidates for senior management roles have the required qualifications and capabilities to fulfill their responsibilities effectively [1] - **Specific Nomination**: The Nomination Committee has agreed to appoint Mr. Xu Ronghuang, Mr. Chen Xiliang, Mr. Zhang Yongzhao, Mr. Wu Weicheng, Mr. Yan Wenge, and Mr. Xu Rongjun as senior management, and Ms. Xu Zilan as the Secretary of the Board [2]

Group 1 - The company held its second extraordinary general meeting of shareholders on July 16, 2025, where five non-employee representative directors were elected to form the sixth board of directors [1] - The sixth board consists of six directors, including four non-independent directors and two independent directors, with the term lasting three years from the date of approval [1][2] - The board's composition meets regulatory requirements regarding the proportion of independent directors and the qualifications of independent director candidates have been approved by the Shenzhen Stock Exchange [1][2] Group 2 - The company appointed senior management personnel, including the general manager, deputy general managers, and the head of the audit department, all for a term of three years [2][3] - The general manager is Mr. Xu Ronghuang, with Mr. Chen Xiliang serving as the deputy general manager and financial director [2][3] - The company’s secretary of the board and securities affairs representative have obtained the necessary qualifications as per regulatory requirements [3] Group 3 - Following the board re-election, Mr. Xu Danqing and Mr. Xu Songqing stepped down from their respective positions but will continue to work within the company [4][5] - Mr. Xu Danqing holds 139,973,400 shares, accounting for 27.30% of the total share capital, while Mr. Xu Songqing holds 40,572,000 shares, representing 7.91% [4][5] - The company expressed gratitude for the contributions made by the departing directors during their tenure [5] Group 4 - The resumes of the newly appointed directors and senior management personnel are available in the attachment, detailing their qualifications and professional backgrounds [5][6] - Mr. Xu Ronghuang, the chairman, has been with the company since 2015 and has held various positions before becoming the general manager [6][13] - The independent directors, including Ms. Zhao Xiaobo and Mr. Lai Hanqi, have no conflicts of interest with major shareholders or other directors [11][12]

Core Viewpoint - The legal opinion letter from Grandall Law Firm (Shenzhen) confirms that the adjustment of the exercise price for the 2021 stock option incentive plan of Te Yi Pharmaceutical Group Co., Ltd. has obtained the necessary approvals and complies with relevant regulations [1][4][5]. Group 1: Approval and Authorization - The board of directors has authorized the adjustment of the exercise price for the stock option incentive plan, which is now set at 6.19 yuan per share [4][5]. - The adjustment is deemed to be in accordance with the provisions of the stock incentive plan and relevant regulations [4][5]. Group 2: Specifics of the Adjustment - The adjustment was necessitated by a cash dividend distribution of 0.50 yuan per 10 shares, with no stock dividends or capital increases [4][5]. - The formula used for the adjustment of the exercise price is P = P0 - V, where P0 is the original exercise price, V is the cash dividend per share, and P is the adjusted exercise price [5]. - Following the adjustment, the exercise price changed from 6.24 yuan per share to 6.19 yuan per share [5]. Group 3: Conclusion - The legal opinion concludes that the adjustment has received the necessary approvals and is in compliance with the relevant laws and regulations [5][6]. - The company is required to fulfill its information disclosure obligations and complete the necessary procedures related to this adjustment [5].

证券代码：002728 证券简称：特一药业 公告编号：2025-050 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2025 年 7 月 16 日召开第六届董事会第一次会议，审议通过了《关于调整 2021 年股票期权激励计划 股票期权行权价格的议案》，现就调整相关事宜公告如下： 一、2021 年股票期权激励计划基本情况 1、2021 年 10 月 12 日，公司召开第四届董事会第二十一次会议，审议通过了《关 于公司<2021 年股票期权激励计划（草案）>及其摘要的议案》《关于公司<2021 年股票 期权激励计划实施考核管理办法>的议案》及《关于提请股东会授权董事会办理 2021 年股票期权激励计划有关事项的议案》。 2、2021 年 10 月 12 日，公司召开第四届监事会第二十一次会议，审议通过了《关 于公司<2021 年股票期权激励计划（草案）>及其摘要的议案》《关于公司<2021 年股票 期权激励计划实施考核管理办法>的议案》及《关于核实<公司 2021 年股票期权激励计 划激励对象名单>的议案》。 3、2021 年 10 月 13 日至 2021 年 10 月 22 日，公司对激励对 ...